Recordati CEO sees ‘substantial opportunity’ in Sanofi drug purchase

Share

Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company’s purchase of Sanofi’s rare immune disorder drug, Enjaymo.

Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *